Repare Therapeutics (NASDAQ:RPTX) Stock

REPARE THERAPEUTICS INC

Repare Therapeutics

Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.

Repare Therapeutics Inc

Goldman Sachs analyst John Mackay maintains Venture Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VG#NYSE">VG</a>) with a Buy and lowers the price target from $20 to $17.5.

News

Price Target

Analyst Ratings

Goldman Sachs Maintains Buy on Venture Global, Lowers Price Target to $17.5

WIIM

ELMD

Electromed shares are trading lower after the company reported worse-than-expected Q3 sales results.

VRCA

Verrica Pharmaceuticals shares are trading lower. The company reported Q1 financial results.

Goldman Sachs analyst Caitlin Burrows maintains Safehold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAFE#NYSE">SAFE</a>) with a Buy and lowers the price target from $28 to $25.

SAFE

Goldman Sachs Maintains Buy on Safehold, Lowers Price Target to $25

LXRX

Lexicon Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q1 sales results.

Goldman Sachs analyst Eric Sheridan maintains Roblox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) with a Neutral and raises the price target from $63 to $80.

RBLX

Goldman Sachs Maintains Neutral on Roblox, Raises Price Target to $80

SLND

Southland Holdings shares are trading higher after the company reported better-than-expected Q1 financial results.

RBC Capital analyst Luca Issi reiterates Allogene Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLO#NASDAQ">ALLO</a>) with a Outperform and maintains $10 price target.

Reiteration

ALLO

RBC Capital Reiterates Outperform on Allogene Therapeutics, Maintains $10 Price Target

Barclays analyst Gena Wang maintains Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) with a Overweight and lowers the price target from $9 to $5.

SGMO

Barclays Maintains Overweight on Sangamo Therapeutics, Lowers Price Target to $5

Goldman Sachs analyst Will Nance maintains Robinhood Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) with a Buy and raises the price target from $56 to $64.

HOOD

Goldman Sachs Maintains Buy on Robinhood Markets, Raises Price Target to $64

PTIX

Protagenic Therapeutics shares are trading lower. The company reported Q1 financial results.

WATT

Energous shares are trading lower. The company reported Q1 financial results.

Goldman Sachs analyst Richard Law maintains Olema Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLMA#NASDAQ">OLMA</a>) with a Buy and lowers the price target from $20 to $18.

OLMA

Goldman Sachs Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $18

ANEB

Anebulo Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 EPS results.

Goldman Sachs analyst Irma Sgarz maintains MercadoLibre (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>) with a Buy and raises the price target from $2640 to $3000.

MELI

Goldman Sachs Maintains Buy on MercadoLibre, Raises Price Target to $3000

MP Materials Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MP#NYSE">MP</a>) shares are trading higher premarket on Wednesday after the company disclosed an agreement with a Saudi Arabian Mining Company (Maaden) to explore opportunities for establishing a fully integrated, <a href="https://www.benzinga.com/pressreleases/25/05/b45404358/maaden-and-mp-materials-collaborate-to-establish-full-value-chain-for-rare-earth-magnetics" target="_blank" rel="noreferrer noopener">end-to-end rare earth supply chain</a>.
This agreement unites the companies&#8217; expertise in exploration and processing to facilitate and mitigate risks in the development of potential Rare Earth Element (REE) deposits throughout Saudi Arabia.
Maaden and MP Materials intend to investigate opportunities to jointly build a vertically integrated rare earth supply chain within Saudi Arabia.
This would encompass mining, separation, refining, and magnet production, with the aim of fostering industrial growth and generating value for downstream industries.
MP Materials CEO James Litinsky, said. &#8220;Today&#8217;s announcement is an important first step towards rebalancing the global supply chain in a moment of transformational growth fueled by emerging technologies—especially in robotics and physical AI—while deepening the strategic alliance between the United States and Saudi Arabia.&#8221;
Bob Wilt, CEO of Maaden, added, &#8220;Through a potential partnership with MP Materials, and our deepening ties with the United States, we aim to create a global hub for a fully integrated rare earth value chain supporting advanced manufacturing in the Kingdom.&#8221;
Last week, MP Materials reported a first-quarter adjusted EPS loss of 12 cents, which was in line with analyst estimates, and sales reached $60.81 million, falling short o<a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45299290/mp-materials-reports-first-quarter-2025-results" rel="noreferrer noopener">f the estimated $63.69 million</a>.
Investors can gain exposure to the stock via Sprott Critical Materials ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SETM#NASDAQ">SETM</a>) and VanEck Rare Earth and Strategic Metals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REMX#NYSE">REMX</a>).
Price Action: MP shares are up 3.08% at $21.42 at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/04/44650952/china-restricts-rare-earth-exports-to-us-as-part-of-tariff-retaliation" target="_blank" rel="noreferrer noopener">China Restricts Rare Earth Exports To US As Part Of Tariff Retaliation: &#8216;Geopolitical Earthquake In Slow Motion,&#8217; CEO Says</a></li>
</ul>
Image: Shutterstock

Equities

Mid Cap

Contracts

Movers

Market Vectors Rare Earth/Strategic Metals Etf

REMX

SETM

From Mine To Magnet: MP Materials, Maaden Plan Rare Earth Chain In Saudi Arabia

FTHM

Fathom Holdings shares are trading higher after the company reported better-than-expected Q1 sales results.

XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) price climbed 5.46% to $2.55 on Tuesday. The <a href="https://www.benzinga.com/money/how-to-buy-ripple-xrp">upward movement extends its weekly gains</a> to 18%, as reported by CoinMarketCap data. A massive spike in trading activity has been the major factor behind XRP&#8217;s price surge.&nbsp;
XRP's trading volume has skyrocketed by nearly 140% in the last 24 hours, and reached a substantial $10.51 billion. Data from Glassnode indicates an increase in XRP futures open interest, which has soared by 41.5% in just seven days to reach $3.42 billion.
Don't Miss:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/go/plus-500-crypto-in-content">Trade crypto futures on Plus500 with up to $200 in bonuses</a> — no wallets, just price speculation and free paper trading to practice different strategies.</li>
<li>New to trading crypto? <a href="http://coinbase-consumer.sjv.io/m5ALXy">Get up to $400 in rewards for successfully completing short educational courses and placing your first qualifying trade</a> on Coinbase.</li>
</ul>
The surge in futures activity often reflects increased speculative interest, and can amplify price movements. "This sharp increase in leverage coincides with a price rally from $2.14 to $2.48, suggesting elevated speculative activity and growing directional conviction," tweeted Glassnode.
Further, on-chain data reveals a potential slowdown in selling pressure from large wallet holders (whales).
The change in whale behavior is considered a significant indicator. According to CryptoQuant, data from Kripto Mevsimi&#8217;s 30-day Whale Flow chart shows a rise in net flows and suggests that large holders are reducing their selling activity, and potentially accumulating more XRP.
"After months of relentless whale outflows, XRP's negative flow trend is finally losing steam — and may be on the verge of flipping positive," said Kripto Mevsimi while sharing the report.
The shift in whale activity has likely contributed to the strengthening of XRP&#8217;s recent rally and increased the probability of a longer-term recovery. Generally, when whales reduce their token selling, it results in sustained upward movements. Hopefully, it will continue to reflect in the price of XRP as well.
Surging trading volume, positive price action, increased futures open interest, and a potential shift in whale accumulation patterns bat for a bullish trajectory of XRP. More than that, community sentiment surrounding XRP has also turned overwhelmingly positive, with 88% of tracked wallet holders expressing a favorable outlook, according to CoinMarketCap.&nbsp;
This aligns with recent wallet growth and indicates rising interest and participation in the XRP ecosystem in 2025. These converging factors suggest that XRP may be poised for further gains in the short to medium term.
Meanwhile, the Chicago Mercantile Exchange (CME) Group, a major derivatives marketplace, has announced that it will launch its XRP futures contracts on May 19. This development is widely viewed as a significant step forward, which could pave the way for the future approval of XRP ETFs.
As noted by TradingView, when CME introduced Bitcoin futures, it led to a significant price surge for BTC. However, the specific effect of CME&#8217;s XRP futures launch on XRP&#8217;s price is currently uncertain. While the long-term impact remains to be seen, the factors mentioned above suggest a potentially promising trajectory for XRP in the near future.
The growing anticipation of favorable legal outcomes, and the possibility of an XRP-spot ETF appear to be significant drivers of this sentiment.
More Opportunities:
<ul class="wp-block-list">
<li>Grow your IRA or 401(k) with Crypto – <a href="https://info.irafinancial.com/lp/irafi-crypto/?utm_source=benzinga.com&amp;utm_medium=affiliate&amp;utm_campaign=y2">unlock the power of alternative investments including a Crypto IRA within your retirement account</a>.</li>
<li>Trade, earn, and grow your crypto portfolio with Crypto.com — <a href="https://www.benzinga.com/go/crypto-com-signup-bonus">plus receive up to $500 worth of rewards in the most popular tokens if you're a new customer</a>.</li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$XRP

XRP Price, Futures Open Interest Skyrockets, Signaling Strong Speculative Activity

Goldman Sachs analyst Caitlin Burrows maintains Lineage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINE#NASDAQ">LINE</a>) with a Buy and lowers the price target from $74 to $63.

LINE

Goldman Sachs Maintains Buy on Lineage, Lowers Price Target to $63

SEER

Seer shares are trading higher after the company reported better-than-expected Q1 financial results.

Press Releases

Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial

Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial

Opinion

How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options

Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions

Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Repare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Repare Therapeutics Announces Leadership Transitions

Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025

Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics

Newly Launched DCx Biotherapeutics In-Licenses Discovery Platforms and Retains Talent and Infrastructure From Repare Therapeutics to Accelerate Development of Multi-Modal Antibody Drug Conjugates

Comments

Repare Therapeutics

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL